Online citations, reference lists, and bibliographies.
← Back to Search

Effects Of Combined Therapies On The Survival Of Pleural Mesothelioma Patients Treated In Brescia, 1982-2006.

P. Barbieri, A. Marinaccio, P. Ferrante, A. Scarselli, V. Pinelli, G. Tassi
Published 2012 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
AIMS AND BACKGROUND During the 1990's, the traditional unimodal treatments (surgery, radiotherapy, chemotherapy, immunotherapy) for malignant pleural mesothelioma started to be combined in bimodal or multimodal strategies. However, recent population-based analyses of the survival of patients with malignant pleural mesothelioma indicate that even these treatments have not led to significant improvements in prognosis, which remains very poor. The present study assessed the survival of patients given combined treatments and multimodal therapies in a specialized hospital department. METHODS The study population comprised 530 patients diagnosed with malignant pleural mesothelioma from 1982 to 2006: 343 of them were residents in the province of Brescia (Lombardy, Northern Italy) and 187 were residents outside the province, with a follow-up to 31 December 2009. Kaplan-Meier survival analyses and Cox proportional risks model were used to test sex, age at diagnosis, histological type and treatments, as prognostic factors. RESULTS The estimated median survival for the whole group of patients was 317 days (257 for residents and 398 for non-residents), and respectively 310 and 340 days in the groups diagnosed in the periods 1982-2000 and 2001-2006. Multivariate analysis confirmed that the prognosis was better for younger patients and cases of epithelioid type malignant pleural mesothelioma, whereas for patients receiving any single treatment the prognosis was not significantly better than for those given palliative care alone. However, patients receiving combined treatments or the multimodality approach had significantly longer median survival and the relative risk of death was respectively 0.57 and 0.61 compared to untreated patients (or those only given symptomatic therapy). CONCLUSIONS This is the first study in Italy to assess the effectiveness of different treatment approaches in a significant number of patients treated in one hospital. Further studies are needed to confirm the improvement in prognosis - even if modest--on larger numbers of patients and taking into account the different stages of the disease.
This paper references
Survival analysis for mesothelioma cases in the Italian register ( Re Na M )
A Marinaccio (2003)
10.1016/S0140-6736(95)90462-X
Continuing increase in mesothelioma mortality in Britain
J. Peto (1995)
Analisi della sopravvivenza dei mesoteliomi maligni trattati a Brescia dal
PG Barbieri (1982)
10.1002/1097-0142(19930715)72:2<410::aid-cncr2820720216>3.0.co;2-g
Prognostic factors of malignant mesothelioma of the pleura
V. de Pangher Manzini (1993)
Analisi della sopravvivenza dei mesoteliomi maligni trattati a Brescia dal 1982 al 2000
PG Barbieri (2004)
Human malignant mesothelioma of the pleura: new perspectives for diagnosis and therapy.
Antonio Procopio (1998)
Survival after malignant mesothelioma . A population - base study in Italy
C Magnani (2002)
10.1053/SONC.2002.30230
Multimodality treatment of diffuse malignant pleural mesothelioma.
L. Zellos (2002)
10.1183/09031936.00063109
Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma
A. Scherpereel (2009)
10.1002/SIM.5511
Contrasting treatment‐specific survival using double‐robust estimators
K. Kim (2012)
NON-PARAMETRIC ESTIMATION FROM INCOMPLETE OBSERVATION
E. Kaplan (1958)
10.1002/1097-0142(19941101)74:9<2460::AID-CNCR2820740912>3.0.CO;2-N
Intrapleural treatment with recombinant gamma‐interferon in early stage malignant pleural mesothelioma
C. Boutin (1994)
10.1177/030089160208800403
Survival after Pleural Malignant Mesothelioma a Population-based Study in Italy
C. Magnani (2002)
10.1200/JCO.1996.14.3.1007
Chemotherapy in malignant pleural mesothelioma. A review.
S. T. Ong (1996)
10.1378/CHEST.113.3.723
Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B.
J. Herndon (1998)
10.1200/JCO.1998.16.1.145
Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience.
D. Curran (1998)
10.1097/00008469-200506000-00001
Survival of malignant pleural mesothelioma cases in the Tuscan Mesothelioma Register, 1988–2000: a population-based study
G. Gorini (2005)
10.1097/00000478-200404000-00013
Well-differentiated Papillary Mesothelioma of the Pleura: A Series of 24 Cases
F. Galateau-Sallé (2004)
10.1016/S0959-8049(03)00233-8
Analysis of survival of mesothelioma cases in the Italian register (ReNaM).
A. Marinaccio (2003)
10.1136/oem.55.11.760
Estimation of the past and future burden of mortality from mesothelioma in France.
A. G. Ilg (1998)
Regression Models and Life-Tables
D.
A pilot Phase II study of cisplatin, doxorubicin, and vindesine for the treatment of malignant pleural mesothelioma
T Nakano (1993)
Linee guida per la rilevazione e la definizione dei casi di mesotelioma maligno e la trasmissione delle informazioni all'Ispesl da parte dei Centri Operativi Regionali. seconda edizione
It Istituto Superiore di Sanit (2004)
[Trends in mortality from primary pleural tumor and incidence of pleural mesothelioma in Italy: a particularly serious situation].
E. Merler (1999)
10.1378/CHEST.116.2.504
Advances in the treatment of malignant pleural mesothelioma.
D. Sterman (1999)
10.1002/ijc.20820
Predictions of mortality from pleural mesothelioma in Italy: A model based on asbestos consumption figures supports results from age‐period‐cohort models
A. Marinaccio (2005)
10.1002/ijc.23874
Survival of pleural malignant mesothelioma in Italy: A population‐based study
F. Montanaro (2009)
10.1097/COC.0b013e3181d31f02
Expert Opinions of the First Italian Consensus Conference on the Management of Malignant Pleural Mesothelioma
C. Pinto (2011)
10.1002/1097-0142(19930715)72:2<410::AID-CNCR2820720216>3.0.CO;2-G
Prognostic factors of malignant mesothelioma of the pleura.
A. Anand (1994)
10.5694/j.1326-5377.1993.tb141344.x
A population based study
P. McIntyre (1993)
10.1378/CHEST.113.1_SUPPLEMENT.61S
Multimodality management of malignant pleural mesothelioma.
D. Sugarbaker (1998)
10.1038/sj.bjc.6601638
The Mesothelioma epidemic in Western Europe: an update
C. Pelucchi (2004)



This paper is referenced by
10.2147/NDT.S48965
Quality of life and personality traits in patients with malignant pleural mesothelioma and their first-degree caregivers
A. Granieri (2013)
10.21037/tlcr.2018.10.02
Combined modality treatment in mesothelioma: a systemic literature review with treatment recommendations.
Charlotte De Bondt (2018)
10.5798/diclemedj.0921.2012.04.0191
Comparison of supportive treatment and pleurodesis in patients with malignant pleural mesothelioma
A. Abakay (2012)
10.1177/0300891618765538
On the diagnosis of malignant pleural mesothelioma: A necropsy-based study of 171 cases (1997–2016)
P. Barbieri (2018)
10.1016/j.cllc.2018.08.019
Moderately Hypofractionated Helical IMRT, FDG–PET/CT‐guided, for Progressive Malignant Pleural Mesothelioma in Patients With Intact Lungs
A. Fodor (2019)
10.1111/1759-7714.13456
Treatment patterns among patients with malignant pleural mesothelioma: An Italian, population‐based nationwide study
A. Trama (2020)
10.1700/1430.15816
Prognostic Factors Affecting Survival in Malignant Pleural Mesothelioma: Analysis of 125 Subjects
B. Komurcuoglu (2014)
10.1016/j.radonc.2017.08.003
The role of radical radiotherapy in the management of malignant pleural mesothelioma: A systematic review.
M. Ashton (2017)
10.1016/j.lungcan.2015.05.014
Treatment patterns and survival analysis in 9014 patients with malignant pleural mesothelioma from Belgium, the Netherlands and England.
R. Damhuis (2015)
Malign plevral mezotelyoma hastalarinda destek tedavisi ve plöredezin karşilaştirilmasi Comparison of supportive treatment and pleurodesis in patients with malignant pleural mesothelioma
Özlem Abakay (2012)
10.1007/s00262-014-1597-9
Activation of CD1d-restricted natural killer T cells can inhibit cancer cell proliferation during chemotherapy by promoting the immune responses in murine mesothelioma
Licun Wu (2014)
10.1016/j.lungcan.2013.11.004
Radiotherapy for the treatment of pain in malignant pleural mesothelioma: a systematic review.
N. Macleod (2014)
Semantic Scholar Logo Some data provided by SemanticScholar